last modified：2025/11/21
Assistant Professor Hiroshi Kotani
Faculty, Affiliation
Cancer Research Institute Division of Innovative Cancer Control Research
Assistant Professor
College and School Educational Field
Laboratory
Division of Cancer Control Research TEL:076-265-2794
Academic Background
Career
Cancer Research Institute of Kanazawa University Division of Cancer Control Research Assistant Professor(2024/08/01-)
Cancer Research Institute of Kanazawa University Division of Medical Oncology Assistant Professor(2021/01/01-2024/07/31)
Takeda Pharmaceutical Company Limited Oncology Clinical Research Department Associate Medical Director(2019/08/01-2020/12/31)
Moffitt Cancer Center and Research Institute Blood and Marrow Transplant and Cellular Immunotherapy Postdoctoral Fellow(2017/07/01-2019/07/31)
Kanazawa University Hospital Cancer Center Assistant Member(2013/04/01-2017/06/30)
Kouseiren Takaoka Hospital Department of Medical Oncology Senior Resident(2010/04/01-2013/03/31)
Kouseiren Takaoka Hospital Junior Resident(2008/04/01-2010/03/31)
Year & Month of Birth
Academic Society
Award
Specialities
Speciality Keywords
Research Themes
Books
Papers
- Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy Hiroshi Kotani;Shigeki Sato;Seiji Yano;Marco L. Davila;Hiroaki Taniguchi Signal Transduction and Targeted Therapy 2025/10/03
- Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers Hiroshi Kotani;Tomoyoshi Yamano;Justin C. Boucher;Shigeki Sato;Hiroyuki Sakaguchi;Koji Fukuda;Akihiro Nishiyama;Kaname Yamashita;Koushiro Ohtsubo;Shinji Takeuchi;Takumi Nishiuchi;Hiroko Oshima;Masanobu Oshima;Marco L. Davila;Seiji Yano Experimental Hematology & Oncology 2024/09/27
- Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage Hiroshi Kotani;Hiroko Oshima;Justin C. Boucher;Tomoyoshi Yamano;Hiroyuki Sakaguchi;Shigeki Sato;Koji Fukuda;Akihiro Nishiyama;Kaname Yamashita;Koushiro Ohtsubo;Shinji Takeuchi;Takumi Nishiuchi;Masanobu Oshima;Marco L. Davila;Seiji Yano Journal of Biomedical Science 2024/07/11
- 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. Journal for ImmunoTherapy of Cancer 2021/10/27
- CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function Justin C. Boucher;Gongbo Li;Hiroshi Kotani;Maria L. Cabral;Dylan Morrissey;Sae Bom Lee;Kristen Spitler;Nolan J. Beatty;Estelle V. Cervantes;Bishwas Shrestha;Bin Yu;Aslamuzzaman Kazi;Xuefeng Wang;Said M. Sebti;Marco L. Davila Cancer Immunology Research 2021/01/01
- Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel Rawan Faramand;Michael Jain;Verena Staedtke;Hiroshi Kotani;Renyuan Bai;Kayla Reid;Sae Bom Lee;Kristen Spitler;Xuefeng Wang;Biwei Cao;Javier Pinilla;Aleksander Lazaryan;Farhad Khimani;Bijal Shah;Julio C. Chavez;Taiga Nishihori;Asmita Mishra;John Mullinax;Ricardo Gonzalez;Mohammad Hussaini;Marian Dam;Brigett D. Brandjes;Christina A. Bachmeier;Claudio Anasetti;Frederick L. Locke;Marco L. Davila Clinical Cancer Research 2020/09/15
- Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy Hamza Hashmi;Christina Bachmeier;Julio C. Chavez;Jinming Song;Mohammad Hussaini;Gabriel Krivenko;Taiga Nishihori;Hiroshi Kotani;Marco L. Davila;Frederick L. Locke;Michael D. Jain British Journal of Haematology 2019/08/13
- 4-1BB enhancement of CAR T function requires NF-κB and TRAFs Gongbo Li;Justin C. Boucher;Hiroshi Kotani;Kyungho Park;Yongliang Zhang;Bishwas Shrestha;Xuefeng Wang;Lawrence Guan;Nolan Beatty;Daniel Abate-Daga;Marco L. Davila JCI Insight 2018/09/20
- Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers Hiroshi Kotani;Yuta Adachi;Hidenori Kitai;Shuta Tomida;Hideaki Bando;Anthony C. Faber;Takayuki Yoshino;Dominic C. Voon;Seiji Yano;Hiromichi Ebi Oncogene 2018/01/19
- Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression H Kotani;H Ebi;H Kitai;S Nanjo;K Kita;T G Huynh;A Ooi;A C Faber;M Mino-Kenudson;S Yano Oncogene 2015/11/09